Examination of the usefulness of Maspin staining in EUS-FNA specimens for pancreatic cancer

Examination of the usefulness of Maspin staining in EUS-FNA specimens for pancreatic cancer - Examination of the usefulness of Maspin staining in EUS-FNA specimens for pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048015

Enrollment

Registered

2022-06-15

Start date

2021-08-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: People over 20 years old. From April 2015 to December 2017, FNA was performed on a pancreatic mass, and pancreatic cancer was diagnosed. Both Maspin staining and p53 staining were performed, and the prognosis was tracked.

Exclusion criteria

Exclusion criteria: Cases that are not pancreatic cancer, cases that have not been stained with Maspin or p53 with EUS-FNA, and cases in which the prognosis could not be followed.

Design outcomes

Primary

Measure	Time frame
Sensitivity and specificity of Maspin staining for pancreatic cancer in EUS-FNA specimens.	—

Secondary

Measure	Time frame
Additional effect by performing p53 staining and Maspin staining. Examination of clinicopathological factors of Maspin staining.	—

Countries

Japan

Contacts

Public ContactKoh Fukushi

Dokkyo Medical University Department of Gastroenterology

d-fuku-k@dokkyomed.ac.jp0282-87-2147

Outcome results